Nouveautés dans la prise en charge de l’infection à cytomégalovirus chez les patients transplantés [Update on the management of cytomegalovirus infection in transplant recipients]
Fiche du document
12 avril 2023
- doi: 10.53738/REVMED.2023.19.822.726
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2023.19.822.726
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/37057854
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_68BB8D4E0C807
info:eu-repo/semantics/embargoedAccess , Restricted: cannot be viewed until 2024-10-14 , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Citer ce document
D. Neofytos et al., « Nouveautés dans la prise en charge de l’infection à cytomégalovirus chez les patients transplantés [Update on the management of cytomegalovirus infection in transplant recipients] », Serveur académique Lausannois, ID : 10.53738/REVMED.2023.19.822.726
Métriques
Partage / Export
Résumé
Cytomegalovirus (CMV) infection remains a significant infectious complication after transplantation. In this article, we summarize the recent advances in the management of CMV infection in solid-organ and hematopoietic stem-cell transplant recipients. Firstly, recent trials have better delineated the indications for the preventive strategies available, namely antiviral prophylaxis and the preemptive approach. Secondly, the antiviral armamentarium has been expanded with the advent of less toxic oral drugs that are available for antiviral prophylaxis and for therapy of refractory/resistant CMV infection. Finally, increasing evidence suggests that cell-mediated immune assays can be used in routine care for individualizing the prevention strategies against CMV.